CTSF
Basic information
Region (hg38): 11:66563464-66568879
Links
Phenotypes
GenCC
Source:
- neuronal ceroid lipofuscinosis 13 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 13 (Supportive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 13 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 13 (Limited), mode of inheritance: Unknown
- adult neuronal ceroid lipofuscinosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Neuronal ceroid lipofuscinosis 13 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Neurologic | 20301601; 23297359 |
ClinVar
This is a list of variants' phenotypes submitted to
- Neuronal ceroid lipofuscinosis 13 (6 variants)
- not provided (2 variants)
- Neuronal ceroid lipofuscinosis (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CTSF gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 34 | 38 | ||||
missense | 86 | 95 | ||||
nonsense | 9 | |||||
start loss | 0 | |||||
frameshift | 11 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 2 | 6 | 1 | 9 | ||
non coding | 25 | 11 | 36 | |||
Total | 10 | 12 | 91 | 64 | 17 |
Highest pathogenic variant AF is 0.0000197
Variants in CTSF
This is a list of pathogenic ClinVar variants found in the CTSF region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-66563698-C-T | Benign (Jul 17, 2018) | |||
11-66563714-TACC-T | Likely benign (Jul 21, 2018) | |||
11-66563938-C-G | Uncertain significance (Mar 09, 2021) | |||
11-66563944-C-T | Uncertain significance (Feb 24, 2022) | |||
11-66563946-G-A | Inborn genetic diseases | Uncertain significance (Apr 27, 2022) | ||
11-66563949-G-A | Neuronal ceroid lipofuscinosis 13 | Uncertain significance (Mar 29, 2024) | ||
11-66563961-G-C | Inborn genetic diseases | Uncertain significance (Jun 23, 2017) | ||
11-66563974-A-T | Inborn genetic diseases | Uncertain significance (Feb 07, 2018) | ||
11-66563980-C-T | Uncertain significance (Sep 09, 2021) | |||
11-66563981-G-A | Neuronal ceroid lipofuscinosis 13 • Inborn genetic diseases | Benign/Likely benign (May 01, 2024) | ||
11-66563987-A-G | not specified • Neuronal ceroid lipofuscinosis 13 • Inborn genetic diseases | Benign (Jan 30, 2024) | ||
11-66563987-ACG-GCA | Inborn genetic diseases | Uncertain significance (Apr 26, 2019) | ||
11-66563989-G-A | Neuronal ceroid lipofuscinosis 13 • Inborn genetic diseases | Uncertain significance (Oct 20, 2023) | ||
11-66564068-GC-G | Neuronal ceroid lipofuscinosis 13 | Likely benign (May 23, 2022) | ||
11-66564075-C-T | Neuronal ceroid lipofuscinosis 13 | Likely benign (Jan 28, 2024) | ||
11-66564093-C-T | Inborn genetic diseases | Uncertain significance (Oct 13, 2023) | ||
11-66564095-C-G | Neuronal ceroid lipofuscinosis 13 | Pathogenic (Apr 01, 2013) | ||
11-66564095-C-T | Inborn genetic diseases | Uncertain significance (May 31, 2023) | ||
11-66564098-C-T | not specified | Uncertain significance (Dec 14, 2021) | ||
11-66564100-G-A | not specified • Inborn genetic diseases • Neuronal ceroid lipofuscinosis 13 | Benign/Likely benign (Jan 19, 2024) | ||
11-66564105-T-C | Uncertain significance (Nov 08, 2019) | |||
11-66564110-C-T | not specified | Uncertain significance (Jul 26, 2021) | ||
11-66564117-TC-T | Neuronal ceroid lipofuscinosis 13 | Uncertain significance (Feb 08, 2018) | ||
11-66564119-T-C | Uncertain significance (Feb 03, 2022) | |||
11-66564138-C-T | Inborn genetic diseases | Likely benign (Mar 14, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CTSF | protein_coding | protein_coding | ENST00000310325 | 13 | 5379 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.94e-13 | 0.112 | 125693 | 0 | 55 | 125748 | 0.000219 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.744 | 217 | 250 | 0.868 | 0.0000145 | 3086 |
Missense in Polyphen | 88 | 113.43 | 0.7758 | 1329 | ||
Synonymous | -0.246 | 105 | 102 | 1.03 | 0.00000625 | 959 |
Loss of Function | 0.753 | 22 | 26.2 | 0.841 | 0.00000121 | 304 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000518 | 0.000518 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000875 | 0.000870 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000132 | 0.000132 |
Middle Eastern | 0.000875 | 0.000870 |
South Asian | 0.000393 | 0.000392 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. Has also been implicated in tumor invasion and metastasis.;
- Pathway
- Lysosome - Homo sapiens (human);Apoptosis - Homo sapiens (human);MHC class II antigen presentation;Immune System;Adaptive Immune System
(Consensus)
Recessive Scores
- pRec
- 0.152
Intolerance Scores
- loftool
- 0.466
- rvis_EVS
- 0.49
- rvis_percentile_EVS
- 79.46
Haploinsufficiency Scores
- pHI
- 0.133
- hipred
- N
- hipred_score
- 0.123
- ghis
- 0.441
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.199
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ctsf
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype;
Gene ontology
- Biological process
- proteolysis;antigen processing and presentation of exogenous peptide antigen via MHC class II;proteolysis involved in cellular protein catabolic process
- Cellular component
- extracellular space;lysosome;lysosomal lumen;extracellular exosome;extracellular vesicle
- Molecular function
- cysteine-type endopeptidase activity